This report was first published by Endpoints News. To see the original version, click here
RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for two related autoimmune conditions called Graves’ disease and thyroid eye disease.
As part of the deal, RTW startup Yarrow Bioscience will pay GenSci, a subsidiary of China’s Changchun High?Tech Industries, $70 million upfront and $50 million in near-term milestones. The total deal is worth as much as $1.365 billion. In exchange, Yarrow will get ex-China rights to an experimental antibody called GS-098.
您已閱讀30%（601字），剩余70%（1413字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。